What to Expect of Biogen's (BIIB) Aduhelm Review by Centers For Medicare and Medicaid Services

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. SMCI
6. GOOGL
7. RTX
8. COF
9. TSLA
10. META

Go back to What to Expect of Biogen's (BIIB) Aduhelm Review by Centers For Medicare and Medicaid Services

Expert Panel Unanimously Decides Biogen's (BIIB) Aduhelm Offers no Patient Benefit

July 15, 2021 5:38 PM EDT

(Updated - July 15, 2021 6:00 PM EDT)

Shares of Biogen (NASDAQ: BIIB) are losing 3% after-hours following a unanimous vote by a panel of prominent medical experts claiming the company's recently approved Alzheimer's drug Aduhelm offers no patient benefit.

In a recent meeting held by the... More